Brief: UK's MHRA Approves Triple Combination Of Deutivacaftor/Tezacaftor/Vanzacaftor For Cystic Fibrosis
07/03/2025 11:39
March 7 (Reuters) - MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY: UK'S MHRA SAYS TRIPLE COMBINATION MEDICINE DEUTIVACAFTOR/TEZACAFTOR/VANZACAFTOR APPROVED FOR CYSTIC FIBROSIS UK'S MHRA SAYS TRIPLE COMBINATION MEDICINE TO TREAT CYSTIC FIBROSIS IN PEOPLE AGED SIX YEARS AND OLDER WHO HAVE SPECIFIC MUTATIONS Source text: [ID:] Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31